Jean‐Marc Barret

1.6k total citations
43 papers, 1.3k citations indexed

About

Jean‐Marc Barret is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Jean‐Marc Barret has authored 43 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 17 papers in Oncology and 5 papers in Organic Chemistry. Recurrent topics in Jean‐Marc Barret's work include Cancer therapeutics and mechanisms (19 papers), DNA Repair Mechanisms (6 papers) and Cancer Treatment and Pharmacology (6 papers). Jean‐Marc Barret is often cited by papers focused on Cancer therapeutics and mechanisms (19 papers), DNA Repair Mechanisms (6 papers) and Cancer Treatment and Pharmacology (6 papers). Jean‐Marc Barret collaborates with scholars based in France, Germany and Belgium. Jean‐Marc Barret's co-authors include Anna Kruczynski, Bridget T. Hill, Chantal Etiévant, Christian Bailly, Alain Duflos, Stéphane Vispé, Nicolas Guilbaud, Dominique Perrin, Thierry Imbert and Bernard Salles and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Jean‐Marc Barret

42 papers receiving 1.2k citations

Peers

Jean‐Marc Barret

ONCOL

TOXIC

Ajita Singh United States

T. E. Witzig United States

Yongxia Zhu China

Ranjan Preet India

Siddhartha Kar United States

Ribo Guo United States

Ki Deok Shin South Korea

Karen TenDyke United States

Rajeshwari R. Mehta United States

Zhengduo Yang China

Ajita Singh United States

Jean‐Marc Barret

1.3k ×1.4

464 ×1.2

ONCOL

180 ×0.8

133 ×1.1

87 ×0.8

TOXIC

Citations per year, relative to Jean‐Marc Barret Jean‐Marc Barret (= 1×) peers Ajita Singh

Countries citing papers authored by Jean‐Marc Barret

Since Specialization

Citations

This map shows the geographic impact of Jean‐Marc Barret's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Marc Barret with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Marc Barret more than expected).

Fields of papers citing papers by Jean‐Marc Barret

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Marc Barret. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Marc Barret. The network helps show where Jean‐Marc Barret may publish in the future.

Co-authorship network of co-authors of Jean‐Marc Barret

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Marc Barret. A scholar is included among the top collaborators of Jean‐Marc Barret based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Marc Barret. Jean‐Marc Barret is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Allain, Thibault, Olivier Dubreuil, G. R. Noel, et al.. (2021). Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation. Cancers. 13(8). 1845–1845. 7 indexed citations

Cutsem, Eric Van, Bohuslav Melichar, Marc Van den Eynde, et al.. (2019). Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor-Associated Macrophage engagement in advanced/metastatic colorectal cancers. Annals of Oncology. 30. iv153–iv154. 5 indexed citations

Clorennec, Christophe Le, Yassamine Lazrek, Olivier Dubreuil, et al.. (2019). ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells. Cell Communication and Signaling. 17(1). 106–106. 13 indexed citations

Clorennec, Christophe Le, Hervé Bazin, Olivier Dubreuil, et al.. (2017). Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3. Molecular Cancer Therapeutics. 16(7). 1312–1323. 13 indexed citations

Bailly, Christian, et al.. (2011). An Integrated Drosophila Model System Reveals Unique Properties for F14512, a Novel Polyamine-Containing Anticancer Drug That Targets Topoisomerase II. PLoS ONE. 6(8). e23597–e23597. 12 indexed citations

Annereau, Jean‐Philippe, Charles Dumontet, Thierry Imbert, et al.. (2010). A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment. Leukemia Research. 34(10). 1383–1389. 29 indexed citations

Vispé, Stéphane, Laurent Créancier, Jesper Q. Svejstrup, et al.. (2009). Triptolide is an inhibitor of RNA polymerase I and II–dependent transcription leading predominantly to down-regulation of short-lived mRNA. Molecular Cancer Therapeutics. 8(10). 2780–2790. 141 indexed citations

Kruczynski, Anna, Arnaud Marchand, Stéphane Vispé, et al.. (2009). Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase. Anti-Cancer Drugs. 20(5). 364–372. 6 indexed citations

Annereau, Jean‐Philippe, Stéphane Vispé, Nicolas Guilbaud, et al.. (2009). Synthesis of conjugated spermine derivatives with 7-nitrobenzoxadiazole (NBD), rhodamine and bodipy as new fluorescent probes for the polyamine transport system. Bioorganic & Medicinal Chemistry Letters. 19(9). 2474–2477. 39 indexed citations

10.

Kruczynski, Anna, Isabelle Vandenberghe, Arnaud Pillon, et al.. (2009). Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system. Investigational New Drugs. 29(1). 9–21. 50 indexed citations

11.

Barret, Jean‐Marc, Anna Kruczynski, Stéphane Vispé, et al.. (2008). F14512, a Potent Antitumor Agent Targeting Topoisomerase II Vectored into Cancer Cells via the Polyamine Transport System. Cancer Research. 68(23). 9845–9853. 74 indexed citations

12.

Vispé, Stéphane, Isabelle Vandenberghe, Maxime Robin, et al.. (2007). Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome. Biochemical Pharmacology. 73(12). 1863–1872. 37 indexed citations

13.

Bailly, Christian, Jean‐Marc Barret, & Anna Kruczynski. (2004). Antitumor Pharmacology - Quo Vadis ?. PubMed. 4(5). 389–391.

14.

Etiévant, Chantal, Anna Kruczynski, Jean‐Marc Barret, et al.. (2000). F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemotherapy and Pharmacology. 46(2). 101–113. 24 indexed citations

15.

Hille, B van, Chantal Etiévant, Jean‐Marc Barret, Anna Kruczynski, & Bridget T. Hill. (2000). Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action. Anti-Cancer Drugs. 11(10). 829–841. 17 indexed citations

16.

Etiévant, Chantal, et al.. (1998). Vinflunine (20′,20′-difluoro- 3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Investigational New Drugs. 16(1). 3–17. 62 indexed citations

17.

Barret, Jean‐Marc. (1997). Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplate assay. Carcinogenesis. 18(12). 2441–2445. 19 indexed citations

18.

Ferry, Gilles, et al.. (1994). Substrate phosphorylation capacities of the major tyrosine protein kinase from the human promyelocytic cell line, HL‐60. International journal of peptide & protein research. 43(5). 496–504. 7 indexed citations

19.

Barret, Jean‐Marc, et al.. (1993). Integrated system for the screening of the specificity of protein kinase inhibitors. Biochemical Pharmacology. 46(3). 439–448. 19 indexed citations

20.

Barret, Jean‐Marc, et al.. (1993). Studies of the potency of protein kinase inhibitors on ATPase activities. Chemico-Biological Interactions. 86(1). 17–27. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact